Bulletin
Investor Alert

New York Markets Close in:

Market Pulse Archives

Aug. 20, 2021, 7:01 p.m. EDT

Pfizer, BioNTech stocks rise on report FDA could fully approve COVID-19 vaccine

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Pfizer Inc. (PFE)
  • X
    BioNTech SE ADR (BNTX)

or Cancel Already have a watchlist? Log In

By Wallace Witkowski

Pfizer Inc. /zigman2/quotes/202877789/composite PFE +1.04% and U.S. shares of BioNTech SE /zigman2/quotes/214419716/composite BNTX +0.22% rose in the extended session Friday following reports that the drug makers will likely get full Food and Drug Administration approval for their COVID-19 vaccine sometime next week. Pfizer shares rose more than 2% after hours, following a 0.2% decline to close at $48.72, and BioNTech’s ADRs rallied more than 5%, following a 5.1% gain to close at $348.68. Late Friday, The Wall Street Journal and The New York Times reported that the FDA could approve the vaccine, which up until now has been distributed on an emergency basis, as early as Monday but could possibly go past that if regulators need more time to review data. The Department of Health and Human Services recently announced that a third dose, or a booster, of the vaccine would be available in mid-Septembe r to those who already received their first two shots. Back in July, Pfizer and BioNTech reported encouraging data on a vaccine booster shot targeting the delta variant of the virus.

/zigman2/quotes/202877789/composite
US : U.S.: NYSE
$ 54.10
+0.56 +1.04%
Volume: 15.88M
Jan. 20, 2022 12:59p
P/E Ratio
16.07
Dividend Yield
2.96%
Market Cap
$300.51 billion
Rev. per Employee
$883,274
loading...
/zigman2/quotes/214419716/composite
US : U.S.: Nasdaq
$ 162.02
+0.36 +0.22%
Volume: 2.13M
Jan. 20, 2022 12:59p
P/E Ratio
4.71
Dividend Yield
N/A
Market Cap
$39.21 billion
Rev. per Employee
$8.48M
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.